Terbinafine and Renal Function
Yes, terbinafine is significantly affected by renal function—clearance decreases by approximately 50% in patients with creatinine clearance ≤50 mL/min, and the drug has not been adequately studied in this population, making its use cautionary in renal impairment. 1
Pharmacokinetic Impact of Renal Impairment
Terbinafine clearance is reduced by approximately 50% in patients with renal impairment (creatinine clearance ≤50 mL/min) compared to those with normal renal function. 1 This is clinically significant because:
- Approximately 70% of the administered terbinafine dose is eliminated renally after extensive hepatic metabolism 1
- The drug is highly protein-bound (>99%) and has a prolonged terminal half-life of 200-400 hours due to tissue accumulation in skin and adipose 1
- Reduced clearance leads to higher systemic exposure and potential accumulation with repeated dosing
Clinical Implications and Contraindications
The FDA label explicitly states that terbinafine use has not been adequately studied in patients with creatinine clearance ≤50 mL/min. 1 This lack of safety and efficacy data creates uncertainty about appropriate dosing and monitoring in this population.
The British Association of Dermatologists guidelines note that terbinafine clearance decreases in patients with severe kidney disease, though they focus primarily on hepatic contraindications (active or chronic liver disease is an absolute contraindication). 2
Monitoring Considerations in Renal Impairment
While baseline monitoring focuses on hepatic and hematologic parameters, patients with renal impairment require additional caution due to:
- The potential for drug accumulation with standard dosing 1
- Risk of rare but serious adverse events, including a case report of terbinafine-associated rhabdomyolysis progressing to acute kidney injury requiring dialysis 3
- Lack of established dose-adjustment guidelines for renal impairment 1
Baseline complete blood count and liver function tests should be obtained before initiating terbinafine in all patients, with particular attention to renal function assessment. 4
Special Population: Kidney Transplant Recipients
Limited evidence suggests terbinafine can be used in kidney transplant recipients with acceptable tolerance, though this requires careful monitoring of immunosuppressant levels and renal function. 5 A retrospective study of 13 kidney transplant recipients showed that altered renal parameters were among the main reasons clinicians avoided prescribing oral antifungals, highlighting the clinical uncertainty in this population. 5
Practical Recommendations
For patients with creatinine clearance ≤50 mL/min:
- Consider alternative therapies (topical agents, other systemic antifungals with better-studied renal profiles) when feasible 2
- If terbinafine is deemed necessary, use with extreme caution given the lack of adequate safety data 1
- Monitor renal function closely during treatment, particularly if therapy extends beyond 4-6 weeks 4
- Be vigilant for signs of drug accumulation or adverse effects, including muscle symptoms that could indicate rhabdomyolysis 3
The decision to use terbinafine in renal impairment should weigh the severity of the fungal infection against the unknown risks of reduced drug clearance and potential accumulation. For severe onychomycosis in patients with renal impairment, the risk-benefit calculation may favor treatment, but close monitoring is essential. 5, 6